Business Wire

Booking.com and Antom Partner to Expand Local Payment Options Across Asia

15.1.2025 04:47:00 CET | Business Wire | Press release

Share

Strategic partnership to streamline payment solutions and elevate traveller experience, introducing over 40 new payment methods across 8 key Asian markets

Booking.com, one of the world’s leading travel companies, and Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a strategic partnership which will enhance the payment experience for Booking.com customers by integrating diverse payment options across key markets in Asia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114445080/en/

This partnership will enable Booking.com to deliver a more tailored customer experience while unlocking business opportunities across China’s Hong Kong SAR, Indonesia, Japan, Malaysia, Singapore, South Korea, Thailand, and the Philippines — markets with a combined population of approximately 680 million. Each market presents distinct challenges, including varying payment methods, currencies and regulatory frameworks. Antom helps global merchants like Booking.com navigate this complexity by leveraging its extensive payment channel partnerships and deep knowledge of local payment landscapes.

Antom has established local acquiring capabilities in over 40 countries and regions, enabling businesses to integrate hundreds of payment methods and supports transactions in over 100 currencies. It offers businesses seamless access to a diverse range of global payment options, including credit cards, e-wallets, and local payment solutions. By leveraging AI technology, Antom helps merchants enhance transaction security, optimise foreign exchange risk management, reduce costs, and improve operational efficiency through real-time payments and blockchain solutions. Additionally, Antom provides digitisation and digital marketing solutions to support merchants’ business growth.

Booking.com is committed to making it easier to experience the world, with a smooth and seamless payment process being a key factor in enabling travellers to book with ease and confidence. Through its partnership with Antom, the digital travel platform will make over 40 payment options available over time, including online banking, bank transfers, digital wallets and local card payments. Key mobile wallets such as AlipayHK (Hong Kong SAR, China), Boost (Malaysia), GCash (the Philippines), GrabPay (Singapore), Kakao Pay (South Korea), Naver Pay (South Korea), Touch 'n Go eWallet (Malaysia) and TrueMoney (Thailand) will be the first to be introduced as new payment methods. This added flexibility empowers a wider range of customers to use their preferred payment methods, streamlining the checkout process and ensuring quicker, more seamless transactions - ultimately unlocking travel opportunities for more consumers across Asia Pacific.

By integrating Antom’s multi-currency offerings and cross-border settlement capabilities, Booking.com is empowering its global accommodation providers to expand user reach, and optimise payment acceptance and reconciliation across diverse markets. This collaboration will especially benefit smaller properties and holiday rentals that may lack access to traditional payment infrastructures, enabling them to compete more effectively in the global marketplace.

Daniel Marovitz, Senior Vice President of Fintech, at Booking.com commented, "Partnering with Antom allows us to streamline and enhance the payment experience for our travellers across Asia Pacific, integrating a wider range of local payment options that align with regional preferences. This collaboration reflects our commitment to delivering a seamless travel experience from booking to checkout. We look forward to working with Antom to support local businesses and continue advancing a more connected, innovative payment ecosystem for travel."

“We’re excited to partner with Booking.com to expand payment options, broaden customer reach across diverse markets, and support the platform in better serving the unique needs of each region,” said Gary Liu, General Manager of Antom, Ant International. “This partnership reflects our commitment to making payments more efficient and enabling merchants to unlock new growth opportunities in today’s dynamic landscape.”

About Booking.com
Part of Booking Holdings Inc. (NASDAQ: BKNG), Booking.com’s mission is to make it easier for everyone to experience the world. By investing in the technology that helps take the friction out of travel, Booking.com’s marketplace seamlessly connects millions of travellers with memorable experiences every day. For more information, follow @bookingcom on social media or visit globalnews.booking.com.

About Antom
Ant International’s Antom is the leading payment and digitisation services provider for merchants around the world. It offers one-stop, vertical-specific digital payment solutions to meet the payment needs of merchants of all sizes. Antom has established local acquiring capabilities in over 40 markets, with the flexibility to accept payments in more than 100 currencies. It also provides digital marketing solutions and merchant digitisation services to help merchant in digital operations and to better engage with their customers. To learn more, please visit https://www.antom.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114445080/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye